Journal ArticleDOI
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
Elizabeth Cooney,Elizabeth Cooney,Elizabeth Cooney,Ann C. Collier,Ann C. Collier,Ann C. Collier,Philip D. Greenberg,Philip D. Greenberg,Philip D. Greenberg,Robert W. Coombs,Robert W. Coombs,Robert W. Coombs,J. Zarling,J. Zarling,J. Zarling,D. E. Arditti,D. E. Arditti,D. E. Arditti,M. C. Hoffman,M. C. Hoffman,M. C. Hoffman,Shiu Lok Hu,Shiu Lok Hu,Shiu Lok Hu,Lawrence Corey,Lawrence Corey,Lawrence Corey +26 more
TLDR
The 2 vaccinia-naive subjects vaccinated with HIVAC-1e showed strong T-cell responses to homologous and heterologous strains of whole virus and to recombinant gp160 protein that remained detectable for over a year; antibodies to HIV envelope also developed in both.About:
This article is published in The Lancet.The article was published on 1991-03-09. It has received 342 citations till now. The article focuses on the topics: Orthopoxvirus & Vaccinia.read more
Citations
More filters
Journal ArticleDOI
Heterologous protection against influenza by injection of DNA encoding a viral protein
Jeffrey B. Ulmer,John J. Donnelly,Suezanne E. Parker,Gary Rhodes,Philip L. Felgner,V. J. Dwarki,Stanislaw H. Gromkowski,R. Randall Deck,Corrille M. DeWitt,Arthur Friedman,Linda A. Hawe,Karen R. Leander,Douglas Martinez,Helen C. Perry,John W. Shiver,Donna L. Montgomery,Margaret A. Liu +16 more
TL;DR: To generate a viral antigen for presentation to the immune system without the limitations of direct peptide delivery or viral vectors, plasmid DNA encoding influenza A nucleop protein was injected into the quadriceps of BALB/c mice and resulted in the generation of nucleoprotein-specific CTLs.
Journal Article
Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001.
TL;DR: These revised recommendations regarding vaccinia (smallpox) vaccine update the previous Advisory Committee on Immunization Practices (ACIP) recommendations and include current information regarding the nonemergency use of vaccinia vaccine among laboratory and health-care workers occupationally exposed to vaccinia virus, recombinant vaccinia viruses, and other Orthopoxviruses that can infect humans.
Journal ArticleDOI
Pathogenesis of human immunodeficiency virus infection.
TL;DR: The observations indicate the major challenge of preventing infection by HIV appears to involve infection with a relatively low-virulence strain that remains sensitive to the immune response, particularly to control by CD8+ cell antiviral activity.
Journal ArticleDOI
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
TL;DR: A genetically altered vaccinia virus that is unable to replicate in mammalian cells and produces diminished cytopathic effects retains the capacity for high-level gene expression and immunogenicity while promising exceptional safety for laboratory workers and potential vaccine recipients.
Journal ArticleDOI
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
L. K. Borysiewicz,Alison Nina Fiander,M. Nimako,Stephen Man,Gavin William Grahame Wilkinson,D. Westmoreland,A. S. Evans,Malcolm Adams,Simon N. Stacey,Mike Boursnell,E. Rutherford,Julian Hickling,Stephen Charles Inglis +12 more
TL;DR: Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.
References
More filters
Journal ArticleDOI
Nucleotide sequence of the AIDS virus, LAV
TL;DR: The complete 9193-nucleotide sequence of the probable causative agent of AIDS, lymphadenopathy-associated virus (LAV), has been determined and shows two novel open reading frames the authors call Q and F, which place LAV apart from the previously characterized family of human T cell leukemia/lymphoma viruses.
Journal ArticleDOI
The Purification of Four Strains of Poxvirus.
TL;DR: The purified virus suspensions are homogeneous in density gradients and contain no material reacting serologically as host tissue, and Electron micrographs show that very little material not identifiable as virus particles is present.
Journal ArticleDOI
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.
TL;DR: It is reported that natural antibodies capable of neutralizing HTLV-III infection of H9 cells were detected in most adult AIDS and ARC patients but in no normal healthy heterosexual controls, which suggests that virus neutralizing antibodies may exert an in vivo protective effect.
Journal ArticleDOI
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope
Scott D. Putney,T J Matthews,WG Robey,Debra Lynn,Marjorie Robert-Guroff,Mueller William Thomas,A. J. Langlois,J Ghrayeb,Steven R. Petteway,Kent J. Weinhold +9 more
TL;DR: Immunization with either an Escherichia coli recombinant segment of the human T-cell lymphotropic virus envelope protein (gp 120) or with deglycosylated gp 120 envelope protein produced antibodies that neutralize HTLV-III/LAV infection in vitro, showing that although glycosylation is not required for induction of neutralizing antibodies, it may be important for interaction with CD4, the virus receptor.
Journal ArticleDOI
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.
David J.A. Evans,Jane A. McKeating,Janet Meredith,Karen L. Burke,Kersi Katrak,Ann John,Morag Ferguson,Philip D. Minor,Robin A. Weiss,Jeffrey W. Almond +9 more
TL;DR: The construction and characterization of a poliovirus antigen chimaera containing an epitope from the transmembrane glycoprotein (gp41) of human immunodeficiency virus type 1 (HIV-1) are described and it is suggested that Sabin 1 poliov virus/HIV chimaeras could offer an approach to the development of ah HIV vaccine.